Savior Lifetec (4167) - Total Liabilities
Based on the latest financial reports, Savior Lifetec (4167) has total liabilities worth NT$403.30 Million TWD (≈ $12.71 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Savior Lifetec (4167) cash flow conversion to assess how effectively this company generates cash.
Savior Lifetec - Total Liabilities Trend (2011–2025)
This chart illustrates how Savior Lifetec's total liabilities have evolved over time, based on quarterly financial data. Check 4167 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Savior Lifetec Competitors by Total Liabilities
The table below lists competitors of Savior Lifetec ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BayWa AG vNa
XETRA:BYW6
|
Germany | €9.76 Billion |
|
Midnight Sun Mining Corp
V:MMA
|
Canada | CA$691.56K |
|
Lucky Cement Co
TW:1108
|
Taiwan | NT$4.41 Billion |
|
New Power Plasma Co.Ltd
KQ:144960
|
Korea | ₩567.46 Billion |
|
Barings Participation Investors (the Trust)
NYSE:MPV
|
USA | $25.42 Million |
|
Bossa Ticaret ve Sanayi Isletmeleri TAS
IS:BOSSA
|
Turkey | TL4.23 Billion |
|
Dynamix Corporation Class A Ordinary Shares
NASDAQ:DYNX
|
USA | $11.14 Million |
|
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
|
USA | $32.02 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Savior Lifetec's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4167 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Savior Lifetec's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Savior Lifetec (2011–2025)
The table below shows the annual total liabilities of Savior Lifetec from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$403.30 Million ≈ $12.71 Million |
-53.11% |
| 2024-12-31 | NT$860.02 Million ≈ $27.10 Million |
+87.80% |
| 2023-12-31 | NT$457.96 Million ≈ $14.43 Million |
-56.04% |
| 2022-12-31 | NT$1.04 Billion ≈ $32.82 Million |
-15.01% |
| 2021-12-31 | NT$1.23 Billion ≈ $38.62 Million |
-18.63% |
| 2020-12-31 | NT$1.51 Billion ≈ $47.46 Million |
-17.20% |
| 2019-12-31 | NT$1.82 Billion ≈ $57.32 Million |
+8.71% |
| 2018-12-31 | NT$1.67 Billion ≈ $52.73 Million |
-6.21% |
| 2017-12-31 | NT$1.78 Billion ≈ $56.22 Million |
+35.46% |
| 2016-12-31 | NT$1.32 Billion ≈ $41.51 Million |
-20.32% |
| 2015-12-31 | NT$1.65 Billion ≈ $52.09 Million |
-10.10% |
| 2014-12-31 | NT$1.84 Billion ≈ $57.94 Million |
+34.23% |
| 2013-12-31 | NT$1.37 Billion ≈ $43.16 Million |
+24.18% |
| 2012-12-31 | NT$1.10 Billion ≈ $34.76 Million |
+8.16% |
| 2011-12-31 | NT$1.02 Billion ≈ $32.14 Million |
-- |
About Savior Lifetec
Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more